吉西他滨作为卵巢癌的单药治疗。
Gemcitabine as a single-agent treatment for ovarian cancer.
作者信息
Fowler Wesley C, Van Le Linda
机构信息
Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC 27599, USA.
出版信息
Gynecol Oncol. 2003 Aug;90(2 Pt 2):S21-3. doi: 10.1016/s0090-8258(03)00340-8.
OBJECTIVE
Gemcitabine has shown therapeutic activity in a variety of malignancies, including ovarian cancer. This review summarizes both published and unpublished data on the use of gemcitabine as a single agent in the treatment of ovarian cancer.
METHODS
The results of eight clinical trials of gemcitabine in women with advanced (stage III or IV) ovarian cancer whose disease progressed despite previous heavy treatment (one to four previous courses) with platin-based chemotherapy or taxanes were reviewed.
RESULTS
Gemcitabine, given as a single weekly infusion of 800-1200 mg/m(2) for 3 consecutive weeks, followed by a week of rest, produced at least a partial remission in 11 to 22% of the patients studied. Median survival was prolonged after gemcitabine therapy, and stable disease was documented in 41 to 52% of patients in four of the eight studies reviewed. Toxicity was minimal and was mostly hematologic.
CONCLUSIONS
Gemcitabine is obviously active as monotherapy in patients with recurrent stage III or IV ovarian cancer and appears to be very well tolerated.
目的
吉西他滨已在包括卵巢癌在内的多种恶性肿瘤中显示出治疗活性。本综述总结了已发表和未发表的关于吉西他滨单药治疗卵巢癌的数据。
方法
回顾了八项关于吉西他滨治疗晚期（III期或IV期）卵巢癌女性患者的临床试验结果，这些患者尽管先前接受了以铂类化疗或紫杉烷类药物为主的重度治疗（先前接受过一至四个疗程），疾病仍进展。
结果
吉西他滨以每周一次、800 - 1200 mg/m²的剂量连续输注3周，随后休息1周，在11%至22%的研究患者中产生了至少部分缓解。吉西他滨治疗后中位生存期延长，在八项综述研究中的四项研究中，41%至52%的患者病情稳定。毒性极小，主要为血液学毒性。
结论
吉西他滨作为复发的III期或IV期卵巢癌患者的单一疗法具有明显活性，且耐受性似乎非常良好。
Zotero 插件